Meeting the needs of the patient and consumer
2020欧洲杯时间We have a vision to become the world’s manufacturing partner for healthcare solutions. We are working towards delivering the greatest breadth and highest quality of healthcare manufacturing solutions to meet the clinical and commercial needs of large and small customers alike. As part of this, our recent strategy has been to increase focus on accelerating the growth and development of our Pharma Biotech & Nutrition offering.
Today, we are one of the world’s leading suppliers to the pharmaceutical, biotech and specialty ingredients markets. We focus on preventing and curing illness, by supporting our customers to deliver innovative medicines that help treat or even cure a wide range of diseases, as well as creating a healthier environment. Patients and consumers benefit from how we apply our manufacturing technologies to the healthcare, preservation and protection categories.
Investing in Future Growth in Lonza Pharma Biotech & Nutrition (LPBN)
LPBN continues its accelerated growth trajectory, with an expanding portfolio of customers and offerings. Our focus remains on providing healthcare development and manufacturing solutions, which enable our global customers to deliver advances in global health.
Today, the contract development and manufacturing organization (CDMO) industry is experiencing a time of radical change and disruption, driven by the rate of scientific and technological advancement in the industry. At this time, pharma and biotech companies are increasingly focusing on the breadth and depth of end-to-end solutions that deliver a path to commercialization to save time, manage complexity and gain access to expert knowledge.
As an early entrant to the CDMO market, we have captured and built customer relationships and established a global reputation for quality, reliability and consistent delivery. We are well positioned to increase our competitive advantage through strong investment in growth projects. These include capacity expansions and new technologies supporting the full life cycle of therapies.
Delivering a Customer-Centric Configuration in Lonza Specialty Ingredients (LSI)
2020欧洲杯时间We have worked to develop the structure of the LSI business to more accurately reflect the markets we serve. The business is now set up to be easier to navigate and more accessible to customers, with a leading portfolio of Microbial Control Solutions (MCS), supported by a division dedicated to Specialty Chemicals Services (SCS).
2020欧洲杯时间In LSI, we play in an attractive niche market within the Specialty Chemicals industry and we have expanded beyond our core market of microbial control actives, into microbial formulations and the much larger market of formulation additives. In the coming years, our main growth driver will be the asset-light Microbial Control Solutions business. We aim to extend our digital capabilities – not only to increase internal efficiency, but also to develop new business models and enhance customer engagement.
2020欧洲杯时间Growth will be supported by our strength in innovation, and our capability in fulfilling customer needs in an increasingly complex regulatory environment. We have been at the forefront of innovation and have a strong pipeline of growth projects. Concurrently, we are also focusing on more aspirational initiatives to enhance our long-term competitive advantage.